Anat Kerem-Angel
Keine laufenden Positionen mehr
Karriereverlauf von Anat Kerem-Angel
Ehemalige bekannte Positionen von Anat Kerem-Angel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Youdim Pharmaceuticals Ltd.
 Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Private Equity Investor | 01.01.2004 | 31.12.2010 |
Thrombotech Ltd.
 Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Anat Kerem-Angel
| Tel-Aviv University | Doctorate Degree |
Statistik
International
| Israel | 4 |
Operativ
| Private Equity Investor | 1 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sektoral
| Finance | 2 |
| Health Technology | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Youdim Pharmaceuticals Ltd.
Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Finance |
Thrombotech Ltd.
Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Health Technology |
- Börse
- Insiders
- Anat Kerem-Angel
- Erfahrung
